Cas:1190318-66-1 6-nitro-1H-pyrrolo[3,2-b]pyridine manufacturer & supplier

We serve Chemical Name:6-nitro-1H-pyrrolo[3,2-b]pyridine CAS:1190318-66-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-nitro-1H-pyrrolo[3,2-b]pyridine

Chemical Name:6-nitro-1H-pyrrolo[3,2-b]pyridine
CAS.NO:1190318-66-1
Synonyms:S14-1690;1H-Pyrrolo[3,2-b]pyridine, 6-nitro-;6-nitro-1H-pyrrolo[3,2-b]pyridine;6-Nitro-4-azaindole
Molecular Formula:C7H5N3O2
Molecular Weight:163.133
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:363.4±22.0 °C at 760 mmHg
Density:1.5±0.1 g/cm3
Index of Refraction:1.741
PSA:74.50000
Exact Mass:163.038177
LogP:0.66

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like S14-1690 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Nitro-4-azaindole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Nitro-4-azaindole Use and application,1H-Pyrrolo[3,2-b]pyridine, 6-nitro- technical grade,usp/ep/jp grade.


Related News: We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� 6-nitro-1H-pyrrolo[3,2-b]pyridine manufacturer Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December. 6-nitro-1H-pyrrolo[3,2-b]pyridine supplier Our pharma and biotech offering includes registration and commercialization of products through in-licensing and flexible partnerships. 6-nitro-1H-pyrrolo[3,2-b]pyridine vendor We are pleased to work with Inceptua, given their strong record of administering such programs successfully.�� 6-nitro-1H-pyrrolo[3,2-b]pyridine factory AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said.